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Abstract The purpose of this investigation was to study the 
effect on cap structure for trans-splicing in mammalian cells. The 
early SV40 Bst/Bam pre-mRNA (cRNA) was synthesized in 
vitro in both capped (cap-Bst/Bam-cRNA) and non-capped (Bst/ 
Bam-cRNA) versions and microinjected into the nuclei of TC7 
cells. Trans-splicing was monitored by immnnofluorescence 
staining (Tl-antigen) and by RT-PCR analysis. Cap-Bst/Bam- 
cRNA was trans-spliced with high efficiency, but not the Bst/ 
Bam-cRNA molecules. Northern blot analysis revealed that both 
the capped and uncapped cRNA molecules had similar stability in 
the microinjected cells. The coinjected m7G(5')ppp(5')G cap 
analog did not inhibit the trans-splicing reaction in vivo and did 
not prevent nuclear export of the mRNA. 
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in the second T-antigen exon and generation of a new SV40 
mRNA species by trans-splicing [20,21]. This was the first 
demonstration that mammalian cells also have the capability 
of generating functional mRNA molecules by trans-splicing 
(e.g. T I -mRNA) .  
In this study, we investigated the role of the cap structure 
for trans-splicing in mammalian cells. The Tl -pre mRNA was 
synthesized in vitro with and without the cap structure and 
microinjected into the nuclei of tissue culture cells. These ex- 
periments revealed that only capped pre-mRNA molecules 
were efficiently trans-spliced in vivo but not the cap-minus 
RNA. However, trans-splicing was not inhibited when capped 
pre-mRNA molecules were coinjected together with the 
mTG(5')ppp(5')G cap analog. Furthermore, trans-splicing pre- 
ceded polyadenylation, indicating that 3' RNA processing is 
not essential for trans-splicing. 
I. Introduction 
Although RNA splicing has been extensively analysed dur- 
ing the last two decades (for review, see [1]), it is still not 
certain how the cell-type specific splice site selection is regu- 
lated during alternative cis-splicing or trans-splicing; never- 
theless, it is evident hat this requires not only the small ribo- 
nucleoprotein particles but also multiple alternative splicing 
factors [2 8]. Splice site selection and splicing efficiency 
further depend on various cis-acting elements. In vitro studies 
have revealed that the cap structure, added to all pre-mRNA 
molecules during transcription, positively affects cis-splicing. 
Using HeLa cell extracts to study in vitro mRNA processing, 
it has been demonstrated that on addition of the 
m7G(5')ppp(5')G cap analog the reaction mixture inhibited 
cis-splicing [9 12]. Microinjection experiments, utilizing Xeno- 
pus oocytes as recipients, further indicated that the cap struc- 
ture preferentially facilitates excision of the 5' terminal intron 
in vivo [13,14]. 
Furthermore, splicing and maturation of the 3' terminal 
end are interrelated. Mutations within the polyadenylation 
signal can prevent excision of the 3' terminal intron and 
RNA polyadenylation efficiency can be affected by adjacent 
splice sites [15,16]. Moreover, upstream introns are capable of 
enhancing excision of downstream introns [17] and deletion or 
mutation of regular splice sites frequently induce activation of 
cryptic splice sites [18]. As a consequence, splicing defects are 
frequently the cause of human genetic diseases [19]. 
We observed that the deletion of the first SV40 T-antigen 
exon caused activation of a cryptic 5' splice site, located with- 
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2. Materials and methods 
2.1. DNA constructs 
The pl4-T7 DNA was obtained by inserting the early SV40 BstXI/ 
BamHI (Bst/Bam) 2.2 kb DNA segment into the multiple cloning site 
(AccI/BamHI) of the pSPT19 DNA (Pharmacia), oriented in the same 
sense as the T7 promoter within the plasmid. The pl4A5't-T7 DNA 
was constructed by eliminating the consensus equence (G/GTA 
changed to G/CGC) of the small t-antigen 5' splice site of the p14- 
T7 DNA by site-directed mutagenesis a described elsewhere [20]. The 
pSVT/t-T7 DNA was generated by inserting the early SV40 Bgll/Bam 
2.7 kb DNA segment into the pSPT19 vector as described above and 
the pSVT-T7 contains the early SV40 large T-antigen cDNA. 
2.2. cRNA synthesis 
For runoff cRNA synthesis [22], the DNA constructs pl4-T7, 
pl4A5't-T7, pT7-Bgl/Bam and pSVT-T7 were linearized by SmaI 
treatment which cuts 6 bp downstream from the BamHI site; com- 
pleteness of cleavage was confirmed by Southern blot analysis. In 
vitro transcription including 1 Bg of linearised template DNA, the 
cap nucleotide m7G(5')ppp(5')G (Ambion) and T7 polymerase (T7 
Cap-Scribe; Boehringer Mannheim) was performed according to the 
supplier's protocol. The quality and correct size of the cRNA prep- 
arations were confirmed by Northern blot analysis. The absence of 
any template DNA in the cRNA preparation after RQ-I-DNase (Pro- 
mega) digestion was confirmed by PCR analysis with 1 ng cRNA, the 
SV40 specific primers d (5'GAAATGCCATCTAGTGAT3') and h 
(5'GTTATGATTATAACTGTTATG3') and 3 U Taq polymerase 
(BRL) after 35 PCR cycles (30 s, 94°C; 30 s, 53°C; 1 min, 74°C 
each cycle). Control PCRs included 1 ng reverse-transcribed (RT) 
cRNA. The Southern blots were hybridized with 32p-labelled SV40 
DNA. The primer g (5'GCAAAGATGGATAAAGTTT3') was used 
in combination with the primer w (5'ACTAAACACAGCAT- 
GACT3') to analyze T/t-antigen cis-splicing. The binding site (anti- 
sense) of the primer o (5'CCAGACATGATAAGATAC3') is down- 
stream from the early SV40 polyA site (5' end of primer on SV40 is nt 
2537; cleavage/polyadenylation site is nt 2586). 
2.3. cRNA injection and immunofluorescence 
TC7 or rat 2 cells were microinjected with capped or non-capped 
cRNA molecules (concentration 1 Bg/lal, injection volume 10 s ~tl/cell) 
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and stained for T-antigen as described previously [23]. The cRNA was 
re-extracted from the injected cells and subjected to agarose gel elec- 
trophoresis under denaturing conditions (formamide/formaldehyde 
buffer) and further processed for Northern blot analysis as described 
elsewhere [22 24]. 
3. Results and discussion 
3.1. The cap structure is" essential for trans-splicing in vivo 
As shown in our earlier investigations [20,21], rat cells 
transformed by the early SV40 Bst/Bam DNA fragment 
(p14) that encodes exclusively for the second SV40 T-antigen 
exon (aa 83-708) synthesize two truncated T-antigen mole- 
cules, the TI -  and T2-antigens. The T1 antigen is generated 
by trans-splicing and contains two SV40 T-antigen segments. 
The first segment contains the wt T-antigen amino acid se- 
quence 109 131 and the second one the amino acids 83 708. 
The T2 antigen contains the amino acid sequence 109 708. 
Cells which synthesize the Tl-antigen are maximally trans- 
formed and cells synthesizing only the T2-antigen do not 
grow in soft agar and do not form tumors in nude mice 
(data not shown). 
Since it has been demonstrated that the cap structure is 
essential for cis-splicing in vitro as well as for trypanosomal 
SL-RNA trans-splicing [9 14,25,26], we examined whether the 
cap structure is also required for in vivo trans-splicing in 
mammalian cells. To test this, the SV40 Bst/Bam cRNA was 
synthesized in vitro without having the mZGpppG cap at its 
5'end (Bst/BamA5't-cRNA) and microinjected into the nuclei 
of TC7 and rat 2 cells. About 24 h after injection cells were 
fixed and stained with either the Ab-2 or HPA anti T-anti- 
bodies. The Ab-2 monoclonal antibody recognizes only the 
Tl-antigen and the polyclonal anti-hamster (HPA) recognizes 
both the T1- and the T2-antigens. As summarized in Table l, 
none of the injected cells stained positive after injection of the 
Bst/BamA5't-cRNA. In contrast, intranuclear Tl-antigen ac- 
cumulation was demonstrable when the capped-cRNA (cap- 
Bst/BamA5't-cRNA) was microinjected (Fig. 1). To exclude 
the possibility that increased degradation of the non-capped 
cRNA was the reason for this negative result, the cRNA was 
re-extracted from the injected cells 1.5 h later and subjected to 
Northern blot analysis. These experiments revealed that the 
stability of the non-capped cRNA was not significantly lower 
than that of the capped cRNA (Fig. 2). This is in contrast to 
results obtained from studies with Xenopus oocytes, where 
non-capped RNA molecules were significantly less stable 
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Fig. I. Northern blot analysis. Lanes: l, in vitro synthesized 2.2 kb 
Bst/BamA5't-cRNA; 2, cap-Bst/BamA5't-cRNA re-extracted from 
microinjected TC7 cells; 3, Bst/BamA5't-cRNA reextracted from mi- 
croinjected TC7 cells. The blot was hybridized with the early SV40 
Bgl/Bam DNA fragment. 
than their capped counterparts after intranuclear injection 
[271. 
To prove directly whether the cap structure is essential for 
trans-splicing, recipient cells were lysed 2 3 h after intranu- 
clear cRNA transfer and the re-extracted RNA was subjected 
to RT-PCR analysis using the primer pair b and d for the 
DNA amplification reaction. These primers bind upstream 
and downstream form the 5' cryptic splice site at a distance 
of 258 bp from each other on the wt SV40 DNA. With the 
T I -cDNA as template the PCR generates a 405 bp DNA 
segment [20]. As shown in Fig. 3A (lane 2) only synthesis of 
the 258 bp DNA segment was demonstrable. This DNA seg- 
ment was generated from the unspliced cRNA. 
It has further been demonstrated that cis-splicing can be 
inhibited by an excess of the mZGpppG cap analog [9]. The 
prevailing view derived from in vitro and in vivo experiments 
Table 1 
Percentage of T-antigen positive cells 
Cells injected with Injected into Percentage of T-antigen positive cells 
H PA-stained Ab-2-stained 
cap-Bst/BamA5't-cRNA nuclei 50-60 20-30 
Bst/BamA5't-cRNA nuclei 0 0 
Bst/BamA5't-cRNA cytoplasm 0 0 
cap-Bst/BamA5't-cRNA+cap analog nuclei 50 60 20 30 
cap-T-cRNA cytoplasm 70-80 70 80 
cap-T-cRNA nuclei 60 70 60 70 
T-cRNA nuclei 2-4 2-4 
T-cRNA cytoplasm 40 50 40 50 
SV40-cap-cRNA nucleus 70 80 7~80 
SV40-cap-cRNA+cap nalog nucleus 70-80 70 80 
TC7 cells were fixed and stained for T-antigen 6 h after cRNA injection. The hamster polyclonal antiserum (HPA) allows detection of both the T2- 
and Tl-antigen, whereas the mouse monoclonal antibody Ab-2 exclusively monitors Tl-antigen synthesis. The wt SV40 T-antigen is recognized by 
both types of antisera. 
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808 bp distant from each other at the SV40 DNA. After ex- 
cision of the large T-antigen intron the distance is 462 nucleo- 
tides and with the small t-antigen-specific cDNA as template 
the PCR generates a 742 bp segment. As shown in Fig. 3 both 
cis-splice products were obtained after injection of the SV40 
cap-cRNA, regardless of whether or not the cap analog was 
coinjected (Fig. 3B, lanes 3,4). However, when the non-capped 
SV40-cRNA was injected the large T-antigen and small t-anti- 
gen cis-splicing were not demonstrable (Fig. 3B, lane 2). 
A 
cap and t rans-sp l ic ing 
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cap and c is -sp l ic ing 
Fig. 2. (A) TC7 cells microinjected with the cap-Bst/BamA5't- 
cRNA. (B) TC7 cells microinjected with the Bst/BamA5't-cRNA. 
Cells were fixed and stained with the Ab-2 anti T-antigen antibodies 
24 h after intranuclear cRNA injection. 
is that cap-binding factors (CBP) are involved at an early 
stage of spliceosome assembly [13]. To test whether trans- 
splicing is also inhibited by the cap analog in mammalian 
cells, the mTGpppG dinucleotide was coinjected into the nu- 
clei of TC7 cells at a 1000-2000-fold molar excess together 
with the cap-Bst/BamA5't-cRNA. 2 h after injection the RNA 
was re-extracted and subjected to RT-PCR analysis. With the 
primer pair d and b, PCR generated the 405 bp DNA segment 
with an efficiency similar to that occurring after injection of 
cap-Bst/BamzX5't-cRNA without the cap analog (Fig. 3A 
lanes 3,4), showing that trans-splicing occurred despite the 
high cap analog concentration (100 000-200 000 molecules). 
We also investigated whether the cap analog prevents large 
T-antigen and small t-antigen cis-splicing in vivo. To this end 
the entire early SV40 coding region was cloned (pSVT/t-T7) 
and transcribed in vitro in both the capped (SV40 cap-cRNA) 
and non-capped (SV40-cRNA) version and microinjected into 
the nuclei of TC7 cells. The SV40-cRNA was then re-ex- 
tracted 3 h later and converted into cDNA. For DNA ampli- 
fication the primer pair g and w was used. These primers are 
- - - -  808 
" - "  742 
- - -  462 
1 2 3 4 
Fig. 3. (A) Correlation between the cap structure and TI-mRNA 
trans-splicing efficiency. RT-PCR analysis. Lanes: 1, RT-PCR prod- 
uct obtained with Bst/Ban~5't-cRNA before microinjection; 2, RT- 
PCR product obtained with the Bst/Ban~5't-cRNA re-extracted 
from microinjected TC7 cells; 3, RT-PCR products obtained with 
the cap-Bst/BamA5't-cRNA re-extracted from microinjected TC7 
cells; 4, RT-PCR products obtained from TC7 cells after co-micro- 
injection of the cap-Bst/BamA5't-cRNA and the cap analog. (B) 
Correlation between the cap structure and large T-antigen and small 
t-antigen mRNA cis-splicing efficiency. RT-PCR analysis. Lanes: 
1, RT-PCR product obtained with SV40 cRNA before microinjec- 
tion; 2, RT-PCR product obtained with the SV40 cRNA re-ex- 
tracted from microinjected TC7 cells; 3, RT-PCR products obtained 
with the SV40 cap-cRNA re-extracted from microinjected TC7 cells; 
4, RT-PCR products obtained from TC7 cells co-microinjected with 
SV40 cap-cRNA and the cap analog. The RT-PCR products were 
separated by agarose gel electrophoresis and subjected to Southern 
blot analysis. The blot was hybridized with the early SV40 Bgl/Bam 
DNA fragment. 
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These results are in contrast with data obtained from in 
vitro splicing experiments where it was shown that the cap 
analog at 10 gM concentration mediated 90% inhibition of 
the cis-splicing reaction [9]. Likewise, in microinjected oocytes 
the cap analog acted as a strong competitor for cis-splicing at 
a 70-fold molar excess over the coinjected capped pre-mRNA 
[13]. It was, therefore, an unexpected result that both large T- 
antigen cis-splicing and T I -mRNA trans-splicing were not in- 
hibited, although the cap analog was coinjected at a 1000- 
2000 molar excess. This may indicate that in TC7 cells satura- 
tion and competition were not reached at this high concentra- 
tion of the cap analog. Alternatively, TC7 cells may bypass 
the inhibitory effect by means of an as yet undetermined 
mechanism. 
3.2. Nuclear export of the capped TI-mRNA was not inhibited 
by the cap analog 
There is experimental evidence that the cap structure serves 
as a positive signal for nuclear mRNA export and that the 
mTGpppG cap analog can prevent he translocation of pol II 
transcripts from the nucleus into the cytoplasm [28]. To test 
whether the cap analog also inhibits export of the T I -mRNA 
the coinjection experiments described above were repeated. 
We then stained the microinjected TC7 and rat 2 cells and 
observed that intranuclear T-antigen accumulation occurred 
with the same efficiency in terms of number of T-antigen-pos- 
itive cells and intensity of the immunofluorescence staining, 
regardless of whether or not the m7GpppG cap analog was 
coinjected. This indicates that the cap analog at a high con- 
centration did not prevent the nuclear export of the SV40 
mRNA,  as was the case in microinjected Xenopus oocytes [28]. 
3.3. The cap structure is required for efficient ranslation ~[ the 
BstlBamA5' t-c RNA 
We also microinjected the Bst/BamA5't-cRNA into the cy- 
toplasm of TC7 cells and analysed T-antigen synthesis by 
immunofluorescence staining at different points in time after 
the cRNA transfer. However, neither Tl-antigen nor T2-anti- 
gen synthesis was demonstrable under these conditions (Table 
1). In contrast, T2-antigen synthesis occurred when the 
m7GpppG cap structure was added to these cRNA molecules 
by guanyltransferase treatment prior to microinjection. 
To determine whether the cap structure is an absolute pre- 
requisite for translation we synthesized the cap-minus T-anti- 
gen cRNA (T-cRNA) in vitro, utilizing the early SV40 cDNA 
(pSV-T7) as template. The pSV-T7 DNA encodes for the in- 
tact SV40 wt large T-antigen and does not contain the large 
and small T-antigen intron. After cytoplasmic microinjection 
of the non-capped T-cRNA, 40-50% of the recipient cells 
exhibited a clear intranuclear T-antigen-specific fluorescence 
6 h later (Table 1). Following in vitro addition of the cap 
structure to the T -cRNA (cap-T-cRNA), about 70-80% of 
the injected cells stained positive for T-antigen. It is not clear 
why the cap-minus T -cRNA was translated but not the Bst/ 
BamA5't-cRNA. One difference between these two kinds of 
cRNA molecules is the size of the 5' untranslated leader se- 
quence. It may be that the non-capped Bst/BamA5't-cRNA, 
with the 269-nucleotide-long leader sequence is not translata- 
ble without having the 5' m7GpppG sequence, while the T- 
cRNA with a shorter leader sequence (70 nt) can be trans- 
lated, a topic not further addressed in this investigation. 
3.4. Polyadenylation is not essential for trans-splicing 
Finally, we assessed whether polyadenylation is essential for 
trans-splicing. To this end, cRNA molecules re-extracted 1 h 
after injection were converted into cDNA using the primer o 
for reverse transcription and PCR amplification. The primer o 
binds at the 3' end of the cRNA downstream from the T- 
antigen cleavage/polyadenylation site, allowing the differentia- 
tion between 3' processed and unprocessed cRNA molecules. 
Our RT-PCR and DNA sequencing experiments revealed that 
non-polyadenylated cRNA molecules were trans-spliced as 
well, confirming that trans-splicing and polyadenylation can 
occur independently of each other, as in the case of cRNA cis- 
splicing (for review, see [29]). 
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